These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3686466)

  • 1. [Recommendations for improving the predictive value of phase I to III data concerning the clinical and biological tolerance of a new drug].
    Auriche M
    Therapie; 1987; 42(4):335-7. PubMed ID: 3686466
    [No Abstract]   [Full Text] [Related]  

  • 2. Limitations of dose tolerance studies on predictability for phase III.
    Warrington SJ
    Arzneimittelforschung; 1985; 35(5):781-3. PubMed ID: 4026898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug assays in the assessment of the clinical value and safety of new compounds.
    Campbell DB
    Contemp Issues Clin Biochem; 1985; 3():33-60. PubMed ID: 3915972
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical trials in dermatology. The phase I trials].
    Czernielewski J; Queille-Roussel C; Duteil L; Verschoore M; Schaefer H; Revuz J; De Prost Y; Guillaume JC; Ortonne JP
    Therapie; 1991; 46(3):183-7. PubMed ID: 1792649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical trials of drugs without immediate therapeutic objectives].
    Cheymol G
    Ann Med Interne (Paris); 1987; 138(3):173-7. PubMed ID: 3619247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Early identification of the tolerance profile of agents under clinical investigation].
    Palminteri R; Sarazin E; Narbonne G
    Therapie; 1987; 42(4):343-6. PubMed ID: 3317981
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation and recommendations on adaptive dose-ranging trials: highlights from the PhRMA Adaptive Dose-Ranging Studies Working Group.
    Pinheiro J
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):47S-49S. PubMed ID: 20881216
    [No Abstract]   [Full Text] [Related]  

  • 8. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug testing today].
    Domschke S; Domschke W
    Fortschr Med; 1981 Jun; 99(21):814-8. PubMed ID: 7250872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research in the field of clinical pharmacology in the USSR].
    Lakin KM; Makarov VA; Novikova NV
    Farmakol Toksikol; 1982; 45(3):5-12. PubMed ID: 7047211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Priorities in the benefit-risk assessment of new drugs.
    Venning GR
    Adverse Drug React Acute Poisoning Rev; 1984; 3(2):113-21. PubMed ID: 6543414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac repolarization and the safety of new drugs defined by electrocardiography.
    Morganroth J
    Clin Pharmacol Ther; 2007 Jan; 81(1):108-13. PubMed ID: 17186008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dying to live.
    Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical drug research: feasibility, performance and evaluation in practice].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1988 Oct; 132(44):2010-4. PubMed ID: 3185807
    [No Abstract]   [Full Text] [Related]  

  • 17. Laboratory tests during clinical trials.
    Scand J Clin Lab Invest Suppl; 1989; 195():16-8. PubMed ID: 2799277
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical therapeutic trials].
    Mathé G
    Bull Cancer; 1974; 61(2):191-212. PubMed ID: 4619025
    [No Abstract]   [Full Text] [Related]  

  • 19. [Communication and transparency concerning risk-benefit analysis in public health: the example of medication].
    Lehner JP; Meyer F; Juillet Y
    Therapie; 2001; 56(4):335-9. PubMed ID: 11677849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
    André FE; Foulkes MA
    Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.